Ribosomal protein L9 pseudogene 16 (RPL9P16)

Ribosomal protein L9 pseudogene 16 (RPL9P16) is a non-coding genomic sequence classified as a pseudogene in humans, meaning it shares sequence similarity with the functional ribosomal protein L9 (RPL9) gene but does not produce a functional protein product. RPL9P16 is one of multiple processed pseudogenes related to the RPL9 gene dispersed throughout the human genome. Pseudogenes such as RPL9P16 do not encode functional ribosomal proteins and typically have no known protein-coding or regulatory role[7][8]. There are no known disease associations, drug interactions, or direct therapeutic implications for this pseudogene. RPL9P16 is not generally considered a therapeutic target, receptor, enzyme, transporter, or gene product that would be targeted by drugs, since it is classified as a "pseudogene" rather than a protein-coding gene[7]. The term "pseudogene" means that the sequence arose from a duplication or retrotransposition event involving a protein-coding gene (here, RPL9), but it has since lost the ability to encode a functional protein, most often due to disruptive mutations or lack of regulatory elements. There is no evidence in the scientific literature that RPL9P16 is involved in human disease, biological regulatory pathways, or is used as a biomarker, nor is there evidence that any drugs target this sequence. Its nomenclature conforms to genomics standards; it is not a misspelling or improper label, though its presence as a "pseudogene" means it is not a canonical "target" in the typical therapeutic or pharmacological sense[7]. Note: If you were seeking information on the functional ribosomal protein L9, refer to RPL9 (not RPL9P16), which encodes a component of the large (60S) ribosomal subunit implicated in protein synthesis and, in rare disease contexts, in Diamond-Blackfan anemia[1][2][3][9]. RPL9P16 is a distinct, non-functional genomic element and as such does not fit most canonical molecular target frameworks.

Other names

RPL9_3_534RPL9P16